| A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection (NCT05407519) | Anhui Provincial Hospital | 2022-07-25 |
| Ate-Bev Early Response Prediction Model in Advanced HCC (NCT05763277) | Seoul National University Hospital | 2022-07-22 |
| HCC Staging Modified by Tumor Micronecrosis (NCT05739110) | Zhejiang University | 2022-07-15 |
| Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors (NCT04428437) | Humanity & Health Medical Group Limited | 2022-07-02 |
| Intra-arterial Perfusion in Interventional Radiology (NCT05458791) | Palo Alto Veterans Institute for Research | 2022-07-01 |
| Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies (NCT05448222) | First Affiliated Hospital of Wenzhou Medical University | 2022-07-01 |
| M-TACE Treatment for Unresectable Hepatocellular Carcinoma (NCT05875558) | Shanghai Zhongshan Hospital | 2022-07-01 |
| Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC (NCT04911959) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2022-07-01 |
| Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma (NCT05444478) | Sun Yat-sen University | 2022-07-01 |
| Substudy: Interconnection of Arterial Tumor Feeders Through Tumor Sinusoid in HCC (NCT04641637) | Chinese University of Hong Kong | 2022-06-30 |
| SynOV1.1 Intratumoral Injection Study (NCT04612504) | Beijing Syngentech Co., Ltd. | 2022-06-23 |
| Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma (NCT05416073) | The Second Affiliated Hospital of Chongqing Medical University | 2022-06-22 |
| A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors (NCT05256381) | SOTIO Biotech AG | 2022-06-21 |
| Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients (NCT05171335) | The Methodist Hospital Research Institute | 2022-06-20 |
| Utilization of MAsS in Patients Undergoing LT for HCC (NCT05184283) | Columbia University | 2022-06-16 |
| GPC3-CAR-T Cells for the Hepatocellular Carcinoma (NCT04506983) | Beijing Tsinghua Chang Gung Hospital | 2022-06-10 |
| TACE With Dicycloplatin(TP21) in Unresectable HCC (NCT05472896) | Gao-jun Teng | 2022-06-09 |
| Ablation of Hepatocellular Carcinoma: a Nationwide Study (NCT05498779) | Rigshospitalet, Denmark | 2022-06-01 |
| TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC (NCT05250843) | Third Affiliated Hospital, Sun Yat-Sen University | 2022-05-30 |
| Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma (NCT05280444) | Zhongda Hospital | 2022-05-28 |
| CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma (NCT05257590) | TaiRx, Inc. | 2022-05-23 |
| IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation (NCT05339581) | RenJi Hospital | 2022-05-20 |
| Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV) (NCT04745403) | Lion TCR Pte. Ltd. | 2022-05-20 |
| TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer (NCT05220020) | Sun Yat-sen University | 2022-05-18 |
| Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy (NCT05101629) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2022-05-11 |
| Watch and Wait and Surgical Treatment for Clinical Complete Responders After Non-Curative Therapy for Hepatocellular Carcinoma (NCT05349331) | Sun Yat-sen University | 2022-05-05 |
| Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy (NCT05887661) | The First Affiliated Hospital with Nanjing Medical University | 2022-05-01 |
| Multi-Detector CT Angiography With 3D Reconstruction Versus Digital Subtraction Angiography (NCT05304572) | Assiut University | 2022-05-01 |
| Balloon Assisted Transarterial Therapy for Hepatocellular Carcinoma (NCT04780802) | Chinese University of Hong Kong | 2022-05-01 |
| A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma (NCT05363722) | Shanghai Zhongshan Hospital | 2022-05-01 |
| BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy (NCT05250895) | Emory University | 2022-04-28 |
| Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors (NCT05331911) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2022-04-26 |
| PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma (NCT05864105) | Biotheus Inc. | 2022-04-22 |
| A Study of HFB301001 in Adult Patients With Advanced Solid Tumors (NCT05229601) | HiFiBiO Therapeutics | 2022-04-20 |
| International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy (NCT05342350) | Johns Hopkins University | 2022-04-15 |
| Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma (NCT05359861) | Coherus Oncology, Inc. | 2022-04-12 |
| Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma (NCT04945720) | Sun Yat-sen University | 2022-04-11 |
| TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. (NCT05233098) | Boston Scientific Corporation | 2022-04-04 |
| TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma (NCT06232759) | Guangxi Medical University | 2022-04-01 |
| A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma (NCT05203120) | University of Aarhus | 2022-04-01 |
| Liver Cancer Disparities in American Indian and Alaska Native Persons (NCT05304234) | University of Washington | 2022-04-01 |
| Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers (NCT05278195) | Zhongda Hospital | 2022-04-01 |
| Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (NCT05301842) | AstraZeneca | 2022-03-28 |
| Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma (NCT05231382) | Sun Yat-sen University | 2022-03-28 |
| Implication of Long Non-coding RNA HOTTIP Haplotype on Liver Cancer Metastasis (NCT06544005) | Ain Shams University | 2022-03-16 |
| Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma (NCT05317819) | Polaris Group | 2022-03-14 |
| GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC (NCT04864054) | Eureka Therapeutics Inc. | 2022-03-11 |
| Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO (NCT05078047) | UNICANCER | 2022-03-08 |
| Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors (NCT05220722) | TriSalus Life Sciences, Inc. | 2022-03-02 |
| A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma (NCT05185531) | Shandong Cancer Hospital and Institute | 2022-03-01 |
| Pressure-enabled Delivery in Radioembolization (TriNav Study) (NCT05128032) | Massachusetts General Hospital | 2022-03-01 |
| Multi-analyte Blood Test Clinical Trial (NCT05199259) | Helio Genomics | 2022-03-01 |
| Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples (NCT05171439) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2022-03-01 |
| Prospective Cohort for Early Detection of Liver Cancer (NCT05541601) | University of Oxford | 2022-02-23 |
| A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma (NCT05155189) | Zhejiang University | 2022-02-21 |
| Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors (NCT05302921) | Children's National Research Institute | 2022-02-18 |
| Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 (NCT06354387) | China Medical University Hospital | 2022-02-16 |
| Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma (NCT05111314) | Mayo Clinic | 2022-02-11 |
| Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer (NCT05323201) | The Affiliated Hospital of Xuzhou Medical University | 2022-02-10 |
| Utility of Abbreviated Magnetic Resonance Imaging as a Screening Tool for Hepatocellular Carcinoma in Cirrhotic Patients (NCT05716620) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2022-02-08 |
| Immunomonitoring of Interventional Radiology Procedures in the Management of Hepatocellular Carcinoma (NCT04892810) | University Hospital, Grenoble | 2022-02-03 |
| Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative (NCT05113186) | Assistance Publique - Hôpitaux de Paris | 2022-02-02 |
| The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs (NCT06325826) | Egyptian Liver Hospital | 2022-02-01 |
| HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure (NCT05233358) | The Central Hospital of Lishui City | 2022-02-01 |
| OREIOS International Study (NCT05239507) | AstraZeneca | 2022-02-01 |
| A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC (NCT05205629) | Shanghai Zhongshan Hospital | 2022-01-30 |
| Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies (NCT04258566) | National Institutes of Health Clinical Center (CC) | 2022-01-27 |
| Influence of Social Determinants of Health on the Management of HCC in the French National Cohort Study CHIEF (NCT05128123) | University Hospital, Grenoble | 2022-01-21 |
| A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice (NCT05200221) | Shanghai Zhongshan Hospital | 2022-01-19 |
| Holmium-166 Retrospective Collection of Real-World Data (NCT05111795) | Terumo Europe N.V. | 2022-01-17 |
| Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial (NCT05198609) | Sun Yat-sen University | 2022-01-17 |
| The Surveillance of Hepatocellular Carcinoma (NCT05286099) | Chinese PLA General Hospital | 2022-01-15 |
| Efficacy and Safety of T+A+RAD in HCC (NCT05396937) | Fudan University | 2022-01-12 |
| Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma (NCT03988998) | Guangxi Medical University | 2022-01-10 |
| HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT (NCT05166239) | Peking University | 2022-01-10 |
| TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection (NCT05111366) | Xianhai Mao | 2022-01-06 |
| HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation (NCT04455932) | Concord Repatriation General Hospital | 2022-01-01 |
| Pharmacogenetic Study in Hepatocellular Carcinoma Patients. (NCT05291338) | Rehab Werida | 2022-01-01 |
| Lenvatinib Therapy in HCC Patients After LDLT (NCT05572528) | Kaoshiung Chang Gung Memorial Hospital | 2022-01-01 |
| Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study (NCT05202015) | Charite University, Berlin, Germany | 2022-01-01 |
| Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma (NCT05391867) | Sir Salimullah Medical College Mitford Hospital | 2022-01-01 |
| Role of DEB-TACE Versus c-TACE in Treatment of HCC (NCT05093920) | Sohag University | 2022-01-01 |
| Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots (NCT07312162) | University of Southern California | 2022-01-01 |
| Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone (NCT04710641) | Mina Alpha Limited | 2022-01-01 |
| Prognostic Role of HVPG and ICG-R15 in the Short- and Medium-term Results of the Surgery of HCC on Cirrhosis (NCT05800561) | Federico II University | 2022-01-01 |
| Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning (NCT05257694) | Ping Liang | 2022-01-01 |
| Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma (NCT05105815) | Huashan Hospital | 2021-12-31 |
| A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients (NCT05441475) | Abbisko Therapeutics Co, Ltd | 2021-12-30 |
| Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment (NCT05113290) | First Affiliated Hospital Xi'an Jiaotong University | 2021-12-28 |
| Non-contrast Abbreviated MRI for Secondary Surveillance of HCC (NCT05690451) | Seoul National University Hospital | 2021-12-28 |
| Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC (NCT05134532) | CHA University | 2021-12-24 |
| Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. (NCT05171166) | Peking University | 2021-12-24 |
| Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After HAIC for Locally Advanced HCC (NCT05002452) | Sun Yat-sen University | 2021-12-20 |
| Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy (NCT05197504) | CHA University | 2021-12-20 |
| Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer (NCT05292443) | Geneplus-Beijing Co. Ltd. | 2021-12-20 |
| TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer (NCT05550025) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-12-17 |
| Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors (NCT04767906) | University of Leipzig | 2021-12-14 |
| GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies (NCT05003895) | National Cancer Institute (NCI) | 2021-12-08 |
| Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant (NCT05027425) | University of Cincinnati | 2021-12-07 |
| Donafenib Plus Sintilimab for Advanced HCC (NCT05162352) | Second Affiliated Hospital of Guangzhou Medical University | 2021-12-04 |